Kalaris Therapeutics (KLRS) Cash from Operations (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Cash from Operations of 11581000.0 for Q1 2026, down 56.5% year-over-year from 26622988.51 in Q1 2025, and down 63.41% quarter-over-quarter from 7087000.0 in Q4 2025.
Kalaris Therapeutics (KLRS) Cash from Operations (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Cash from Operations history runs 8 years deep, the most recent figure standing at 11581000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 56.5% year-over-year to 11581000.0; the TTM figure through Mar 2026 stood at 42581000.0 (down 80.43% YoY), while the FY2025 annual figure was 38400000.0, down 85.51% from the prior year.
- Cash from Operations for Q1 2026 stood at 11581000.0, down from 7087000.0 in the prior quarter.
- The five-year high for Cash from Operations was 4000000.0 in Q2 2024, with the low at 46476000.0 in Q1 2022.
- The 5-year median for Cash from Operations is 12600000.0 (2025), against an average of 19834352.94.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations jumped 87.47% in 2024, then slumped 215.0% in 2025.
- Kalaris Therapeutics' Cash from Operations stood at 31571000.0 in 2022, then rose by 2.65% to 30735000.0 in 2023, then surged by 74.36% to 7881000.0 in 2024, then grew by 10.07% to 7087000.0 in 2025, then slumped by 63.41% to 11581000.0 in 2026.
- Business Quant data shows KLRS's Cash from Operations at 11581000.0 in Q1 2026, 7087000.0 in Q4 2025, and 11313000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | -11.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -11.03 Mn |
| Jun 30, 2026 | -11.03 Mn |
| Mar 31, 2026 | -11.58 Mn |
| Mar 31, 2026 | -11.58 Mn |
| Dec 31, 2025 | -7.09 Mn |
| Dec 31, 2025 | -7.09 Mn |
| Sep 30, 2025 | -11.31 Mn |
| Sep 30, 2025 | -11.31 Mn |
| Jun 30, 2025 | -12.60 Mn |
| Jun 30, 2025 | -12.60 Mn |
| Mar 31, 2025 | -7.40 Mn |
| Mar 31, 2025 | -7.40 Mn |
| Dec 31, 2024 | -7.88 Mn |
| Dec 31, 2024 | -7.88 Mn |
| Sep 30, 2024 | -4.32 Mn |
| Sep 30, 2024 | -4.32 Mn |
| Jun 30, 2024 | -4.00 Mn |
| Jun 30, 2024 | -4.00 Mn |
| Mar 31, 2024 | -4.50 Mn |
| Mar 31, 2024 | -4.50 Mn |